Citation Impact
Citing Papers
Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers
1999
Targeting of Cyclic AMP Degradation to β 2 -Adrenergic Receptors by β-Arrestins
2002 StandoutScienceNobel
PDE4 cAMP-specific phosphodiesterases
2001
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
2017 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
The Matrix Metalloproteinase 9 (MMP-9) Hemopexin Domain Is a Novel Gelatin Binding Domain and Acts as an Antagonist
2002
ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and Is Inhibited by TIMP-3
2000
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
2000
Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros
1999
Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand
2002 Standout
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
2004 Standout
Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion
2001
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Inflammation and cancer
2002 StandoutNature
mTOR Signaling in Growth Control and Disease
2012 Standout
Gelatinase-mediated migration and invasion of cancer cells
2005
Liver fibrosis
2005 Standout
Catalytic activities of membrane‐type 6 matrix metalloproteinase (MMP25)
2001
Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MT5-MMP
1999
Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1)
1993
Wound healing and its impairment in the diabetic foot
2005 Standout
The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction
1997
Chronic Venous Disease
2006 Standout
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation
1996
Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome
2001
Transient Free Radicals in Iron/Oxygen Reconstitution of Mutant Protein R2 Y122F.
1995
Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes
2001
Cancer Metastasis: Building a Framework
2006 Standout
Tissue inhibitors of metalloproteinases: evolution, structure and function
2000 Standout
MT1‐MMP: A potent modifier of pericellular microenvironment
2005
Structural Basis of the Adaptive Molecular Recognition by MMP9
2002 Nobel
Matrix metalloproteinases in colorectal cancer: Is it worth talking about?
2003
Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells
2009
Abdominal aortic aneurysm
2005 Standout
Three-dimensional Type I Collagen Lattices Induce Coordinate Expression of Matrix Metalloproteinases MT1-MMP and MMP-2 in Microvascular Endothelial Cells
1998
Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151
2005
Matrix Metalloproteinase 1 Interacts with Neuronal Integrins and Stimulates Dephosphorylation of Akt
2004
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
2002
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
Biochemical Characterization of the Catalytic Domain of Membrane-Type 4 Matrix Metalloproteinase
1999
Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity
1996
The biology of VEGF and its receptors
2003 Standout
Kinetic Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2
1997
Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase
1999
Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family
1994
Local proteolytic activity in tumor cell invasion and metastasis
2005
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme
1995
Primary open-angle glaucoma
2004 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Membrane type-matrix metalloproteinases and tumor progression
2004
Membrane‐Type‐2 Matrix Metalloproteinase Can Initiate the Processing of Progelatinase A and is Regulated by the Tissue Inhibitors of Metalloproteinases
1997
Cleft lip and palate
2009 Standout
DDR2 receptor promotes MMP-2–mediated proliferation and invasion by hepatic stellate cells
2001
TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo
2000
Angiotensin II induces MMP-2 in a p47phox-dependent manner
2005
Identification and Characterization of a Novel Human Matrix Metalloproteinase with Unique Structural Characteristics, Chromosomal Location, and Tissue Distribution
1997
The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms
2001
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Cellular Activation of MMP-2 (Gelatinase A) by MT2-MMP Occurs via a TIMP-2-independent Pathway
2001
Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins
1998
Regulation of matrix metalloproteinases: An overview
2003
Expression of Human Pro-Matrix Metalloproteinase 3 that Lacks the N-terminal 34 Residues in Escherichia coli: Autoactivation and Interaction with Tissue Inhibitor of Metalloproteinase 1 (TIMP-1)
1998
Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor
1998
Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation
1996
Structural properties of matrix metalloproteinases
1999
Inflammation and cancer: back to Virchow?
2001 Standout
Biochemical Characterization of the Catalytic Domain of Human Matrix Metalloproteinase 19
2000
Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.
1996
Different Roles for Plasminogen Activators and Metalloproteinases in Melanoma Metastasis
1996
Inflammation in atherosclerosis
2002 StandoutNature
Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix
2002
Identification of the 183RWTNNFREY191Region as a Critical Segment of Matrix Metalloproteinase 1 for the Expression of Collagenolytic Activity
2000
The Helping Hand of Collagenase-3 (MMP-13): 2.7 Å Crystal Structure of its C-terminal Haemopexin-like Domain
1996
Regulation of membrane type-matrix metalloproteinases
2002
Cell surface association of matrix metalloproteinase-9 (gelatinase B)
2003
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Endometriosis
2004 Standout
TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads
1998
Specific collagenolysis by gelatinase A, MMP‐2, is determined by the hemopexin domain and not the fibronectin‐like domain
2001
The role of gelatinases in colorectal cancer progression and metastasis
2004
Matrix metalloproteinases in tumor invasion and metastasis
2000
Differential Roles of TIMP-4 and TIMP-2 in Pro-MMP-2 Activation by MT1-MMP
2001
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
2007
Cellular activation of proMMP‐13 by MT1‐MMP depends on the C‐terminal domain of MMP‐13
2002
Lectin Domains of Polypeptide GalNAc Transferases Exhibit Glycopeptide Binding Specificity
2011 StandoutNobel
Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2
2000
Cancer-related inflammation
2008 StandoutNature
Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 Å resolution
1998
CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain
2002
MT1-MMP and MMP-7 in invasion and metastasis of human cancers
2003
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion
2007
A helping hand for collagenases: the haemopexin-like domain
1995
The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3
2000
Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B
1994
TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3
1998
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Pathogenesis of endometriosis
2004
Matrix metalloproteinases and tumor metastasis
2006 Standout
Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family Members
1999
Matrix Metalloproteinases
1999 Standout
Molecular Determinants of Metalloproteinase Substrate Specificity: Matrix Metalloproteinase Substrate Binding Domains, Modules, and Exosites
2002
Role of matrix metalloproteinases in melanoma cell invasion
2005
Iron-Catalyzed Reactions in Organic Synthesis
2004 Standout
Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
2003
Endogenous Inhibitors of Angiogenesis
2005
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Geometric and Electronic Structure/Function Correlations in Non-Heme Iron Enzymes
1999 Standout
Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system
2000
Zinc: biological functions and coordination motifs
1993
Evidence of Reciprocal Reorientation of the Catalytic and Hemopexin-Like Domains of Full-Length MMP-12
2008
Gold nanoparticle-enhanced surface plasmon resonance measurement with a highly sensitive quantification for human tissue inhibitor of metalloproteinases-2
2005
DDR2 receptor promotes MMP-2–mediated proliferation and invasion by hepatic stellate cells
2001
Signaling Recognition Events with Fluorescent Sensors and Switches
1997 Standout
Matrix Metalloproteinase 2-Integrin αvβ3 Binding Is Required for Mesenchymal Cell Invasive Activity but Not Epithelial Locomotion: A Computational Time-Lapse Study
2008
Solid phase parallel synthesis of highly substituted thiophene derivatives and identification of novel phosphodiesterase-4 (PDE-4) inhibitors
1999
Matrix Metalloproteinase-2 Production and Its Binding to the Matrix Are Increased in Abdominal Aortic Aneurysms
1998
Review Oncologic, Endocrine & Metabolic: Recent developments in matrix metalloproteinase inhibitors
1995
Cytoskeletal Protein ABP-280 Directs the Intracellular Trafficking of Furin and Modulates Proprotein Processing in the Endocytic Pathway
1997 StandoutNobel
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2
2002
Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate
1995
Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides
1996
Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin
2008
Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity
2001
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
2000
Classification of Intrinsically Disordered Regions and Proteins
2014 Standout
Inflammation and Atherosclerosis
2002 Standout
Recent Advances in Zinc Enzymology
1996 Nobel
A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process
2000
Coupled Folding and Binding with α-Helix-Forming Molecular Recognition Elements
2005
Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
2001
Matrix metalloproteinases: structures, evolution, and diversification
1998
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
Matrix Metalloproteinase Inhibition After Myocardial Infarction
2001
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Mechanical Stretch Enhances mRNA Expression and Proenzyme Release of Matrix Metalloproteinase-2 (MMP-2) via NAD(P)H Oxidase–Derived Reactive Oxygen Species
2003
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant.
1994
Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.
1998
TGF-β3-induced Palatogenesis Requires Matrix Metalloproteinases
2001
Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha.
2000
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Expression and activation of matrix metalloproteinase‐2 (MMP‐2) and its co‐localization with membrane‐type 1 matrix metalloproteinase (MT1‐MMP) correlate with melanoma progression
2000
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
2002
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
1999
Mechanistic Studies on Synthetic Fe−S-Based Clusters and Their Relevance to the Action of Nitrogenases
2005 StandoutNobel
Binding of gelatinases A and B to type-I collagen and other matrix components
1995
Aryl−Aryl Bond Formation One Century after the Discovery of the Ullmann Reaction
2002 Standout
Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia
2009
Recent advances in matrix metalloproteinase inhibitor research
1996
Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease
2005
Works of Thomas Crabbe being referenced
Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin αvβ3 in Angiogenesis In vitro : Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and αvβ3 Are Critical
2005
Reciprocated matrix metalloproteinase activation: A process performed by interstitial collagenase and progelatinase A
1994
The C‐terminal (haemopexin‐like) domain structure of human gelatinase A (MMP2): structural implications for its function
1996
[28] Gelatinases A and B
1995
An in Vivo Model for Screening Peptidomimetic Inhibitors of Gelatinase A
1995
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A
1993
Mutation of the Active Site Glutamic Acid of Human Gelatinase A: Effects on Latency, Catalysis, and the Binding of Tissue Inhibitor of Metalloproteinases-1
1994
CDP840
1998
Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes
1995
The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A
1998
Human progelatinase A can be activated by autolysis at a rate that is concentration‐dependent and enhanced by heparin bound to the C‐terminal domain
1993
Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR
2007
Human progelatinase A can be activated by matrilysin
1994
Regulation of Matrix Metalloproteinase Activitya
1994
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases
1992
Matrix metalloproteinases and metastatic cancer.
1998